spacer
home > ict > spring 2008 > the global player
PUBLICATIONS
International Clinical Trials

The Global Player

Faced with changing clinical trial regulations in India, Nilesh Vite and Arulsingh Jayaraman of Lambda Therapeutic Research assess an initiative to meet tough global standards

The clinical trials industry in India has exploded over the last few years. While regulation presents challenges, it also creates opportunities. In recent times, India has become a major centre for administering clinical trials, and drug companies have realised the potential for outsourcing trials to this region for fast subject recruitment and major cost savings.

The main attraction is the potential to save time and money, with drug tests requiring only one-third to one-half of the cost and duration that would be involved in Europe or the US. To the extent that it enables Indian pharmaceutical companies to maintain a competitive advantage with respect to clinical trials, regulation could be viewed as the cloud with the silver lining.

Beyond these more immediate industry-specific scenarios, the Indian pharmaceutical companies and the Indian government will need to recognise a broader range of fundamental uncertainties that can exert a major impact on India’s overall competitiveness as a country, as well as its specific competitive position in the pharmaceutical industry over the longer term. Internationallyaligned intellectual property (IP) structure and better clinical research regulations are good indicators for multinationals. This will enable companies to develop growth strategies based on encouraging regulatory developments in India.

Compliance with global good clinical practice (GCP) norms requires a global mindset at every level of the process, whether it be a government official approving applications for clinical trials, or an investigator interacting with a recruited patient or volunteer. From a long-term perspective, the accent has to shift from quantity to quality of work. There are signs that this process is already underway.

BACKGROUND

In the last year, it has been acknowledged that the first challenge is to get all the stakeholders in clinical research on a single platform, talking the same language and on the same wavelength – which means the regulatory authorities as well as those responsible for influencing clinical research as a discipline. In the past, they have rarely been consolidated as a group. This unity is important because a comprehensive national agenda for clinical research is required. At most forums, meetings and conferences, a positive conclusion is asserted – and once we go back to work, the same problems arise. But now the scenario is changing, and government is taking the initiative to meet global standards.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Nilesh Vite is a Clinical Trial Auditor in quality assurance for Lambda Therapeutic Research, a CRO in Ahmedabad, India. He is responsible for planning and conducting Phase II and III trial audits as well as framing SOPs and their implementation. He also provides training in the QA aspect of clinical trials, defines the QA programmes, measures compliances, analyses audit observations and makes suggestions for improvements to the clinical trial system. Nilesh graduated from Mumbai University, India, with a degree in Chemistry, Drugs and Dyes, and has a Masters in CLinical Research from the University of Chennai, India. He is currently pursuing an MBA in Marketing from the University of Hariyana, India.

Arulsingh Jayaraman has an Masters in Medical Biochemistry from the University of Calicut, India. A Clinical Trial Auditor in quality assurance for Lambda Therapeutic Research, Arulsingh offers support framing SOPs and their implementation, whilst also taking charge of conducting Phase II and III trial audits, analysing audit observations and measuring compliance.

spacer
Nilesh Vite
spacer
spacer
spacer
Arulsingh Jayaraman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

LINK Medical expands its regulatory services team, strengthening its IMPD & CMC capabilities

LINK Medical, the Northern European clinical research organization (CRO), today announced the expansion of its regulatory team with the recent appointment of new regulatory directors in Norway, Sweden and Denmark
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement